6A. (3 pts) The estimated prevalence of Chronic Myelogenous Leukemia (CML) in 2013 in the United States is 70,000. The e
Posted: Thu Mar 31, 2022 7:58 am
6A. (3 pts) The estimated prevalence of Chronic Myelogenous
Leukemia (CML) in 2013 in the United States is 70,000. The
estimated prevalence of CML is predicted to be 2050 is 181,000,
while the incidence is expected to remain the same as in 2013. What
is a possible cause for the increase in the prevalence of CML in
the US in 2050?
6B. (3 pts) Women (1,788) ages 16 to 23 years underwent testing
for Human Papilloma Virus (HPV) at approximately 6-month intervals
for up to 4 years in the context of phase 3 clinical trial (placebo
arm). HPV type-specific incidence rates were estimated per 100
person-years. HPV-16 exhibited an incidence rate of 5.9 per 100
person-years. The mean cervical infection duration for HPV-16 was
20 months. What is the prevalence of HPV -16 in this
population?
Leukemia (CML) in 2013 in the United States is 70,000. The
estimated prevalence of CML is predicted to be 2050 is 181,000,
while the incidence is expected to remain the same as in 2013. What
is a possible cause for the increase in the prevalence of CML in
the US in 2050?
6B. (3 pts) Women (1,788) ages 16 to 23 years underwent testing
for Human Papilloma Virus (HPV) at approximately 6-month intervals
for up to 4 years in the context of phase 3 clinical trial (placebo
arm). HPV type-specific incidence rates were estimated per 100
person-years. HPV-16 exhibited an incidence rate of 5.9 per 100
person-years. The mean cervical infection duration for HPV-16 was
20 months. What is the prevalence of HPV -16 in this
population?